MedTrace Logo

A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)

NCT02641067 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-02-08

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effect of severe renal impairment on the pharmacokinetics of doravirine.

Conditions

  • Renal Impairment

Interventions

DRUG

Doravirine

Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-26
Primary Completion
2016-05-14
Completion
2016-05-25

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02641067 on ClinicalTrials.gov